Rumor: Pfizer eyeing Enzon bid

Shares of Enzon Pharmaceuticals (ENZN) shot up on the news that Pfizer may be interested in inking a deal with the company. Last year, Enzon sold a manufacturing plant and four marketed products for $300 million in cash to Italy's sigma-tau Group. That left the developer free to focus on its pipeline, which includes metastatic breast cancer drug PEG-SN38. The company recently began Phase II trials of that drug. Its pipeline also includes two Phase I oncology drugs, as well as Oncaspar, which is in Phase I for solid tumors and lymphomas. Neither Enzon nor Pfizer were available to comment on the rumor, according to the Forbes report.

- take a look at this item

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.